Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology.

Keming LinBaijin XiaXuemei WangXin HeMo ZhouYingtong LinYidan QiaoRong LiQier ChenYuzhuang LiJinzhu FengTao ChenCancan ChenXinyu LiHui ZhangLijuan LuBingfeng LiuXu Zhang

Published in: Journal of translational medicine (2024)

In summary, the results of this study suggest that the CAR-T cells derived from high specificity and high affinity Nbs, targeting FGFR4, exhibited significantly enhanced anti-tumor efficacy in vitro and in vivo. This is an exploration of FGFR4 in the field of Nb-derived CAR-T cell therapy for HCC, holding promise for enhancing safety and effectiveness in the clinical treatment of HCC in the future.

Keyphrases

cancer therapy
randomized controlled trial
systematic review
current status
big data
machine learning